In turn, when applied following a combination of RFA and TACE, CIK therapy has been revealed in meta-analysis data to be associated with higher 1-year RFS and 1- and 2-year OS than RFA plus TACE alone (116), and retrospective analyses of HCC patients treated with this triple therapy (n = 85 and n = 58, respectively) demonstrated significantly longer OS and PFS (117) as well as elevated peripheral Tregs and NK cells, lower CD8+ T cell levels, and higher general functioning scores than those who did not receive immunotherapy (118). This evidence concerns the gene CD8A and hepatocellular carcinoma.